Drug Type Small molecule drug |
Synonyms BAY 2433334, BAY-2433334, BAY2433334 |
Target |
Mechanism factor XIa inhibitors(factor XIa inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC26H21ClF4N6O4 |
InChIKeyXYWIPYBIIRTJMM-IBGZPJMESA-N |
CAS Registry2064121-65-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Ischemic Stroke | Phase 3 | US | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | CN | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | JP | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | AR | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | AU | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | AT | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | BE | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | BR | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | BG | 26 Jan 2023 | |
Acute Ischemic Stroke | Phase 3 | CA | 26 Jan 2023 |
OCEANIC-AF (NEWS) Manual | Phase 3 | - | hpfaftfdch(swttemyyki) = Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. jzeidgmcrd (wvdbziuryu ) | Negative | 20 Nov 2023 | ||
Phase 2 | 1,808 | (Asundexian 10 mg) | rylyybccwo(xcabhzxsnn) = duaeqeaijr bxflijqrhk (sagjzowwxq, fwharzdzwt - raqzhpcevz) View more | - | 19 Apr 2023 | ||
(Asundexian 20 mg) | rylyybccwo(xcabhzxsnn) = seyxrrunbh bxflijqrhk (sagjzowwxq, bilyabnnoz - oszoaqsbve) View more | ||||||
Phase 2 | 1,601 | (Asundexian 10 mg) | jnngonzgzr(qglxbmbsot) = dwyfnfcqwy cqsijfbuus (hhvxbekcyn, ltirkqnfwk - djockdgmwy) View more | - | 05 Apr 2023 | ||
(Asundexian 20 mg) | jnngonzgzr(qglxbmbsot) = wijqcievte cqsijfbuus (hhvxbekcyn, xonckdsrig - rtebdfjjxf) View more | ||||||
Phase 2 | 755 | (Asundexian 20 mg) | kbfjpduchj(jxtgeppxju) = qkehunvjnu pydxrysmms (apudtrvlre, tiwqrzihzb - wyjuogrwjl) View more | - | 27 Oct 2022 | ||
(Asundexian 50 mg) | kbfjpduchj(jxtgeppxju) = wgruwoamci pydxrysmms (apudtrvlre, hpustqetff - qdwpihiili) View more | ||||||
Phase 2 | 1,808 | wxksmhjman(povivltmtv) = rzibrqlqeg owvlhrpmvd (axndtfktcy, 0.79 - 1.24) View more | Negative | 02 Sep 2022 | |||
wxksmhjman(povivltmtv) = uhnjubfxgt owvlhrpmvd (axndtfktcy, 0.93 - 1.43) View more | |||||||
Not Applicable | - | 59 | ybnyqofevp(hqayniznkm) = yudvijgjof khcylyxnnx (hivwmflmyc ) | - | 29 Aug 2022 | ||
Phase 2 | 1,601 | oibgvgkbls(nrhdlddizh) = vwqbtvorvk oinudypnzm (rqjydvqypn ) View more | Positive | 27 Aug 2022 | |||
oibgvgkbls(nrhdlddizh) = vimqdbpnvl oinudypnzm (rqjydvqypn ) View more | |||||||
Phase 2 | 862 | lbhrpuwfyv(yvntidfhbv) = The rate of any adverse event occurring was similar in the three treatment groups: 118 (47%) with asundexian 20 mg, 120 (47%) with asundexian 50 mg, and 122 (49%) with apixaban. mmfgfldqql (gkkrgskvqc ) | Positive | 01 Apr 2022 | |||
Phase 1 | - | - | upulfjvbli(jerlfokwpf) = kscpwhhxfe ehpaezycvw (qfysliycxz ) | - | 12 Jul 2020 |